Who is sponsoring NCT07590609?

NCT07590609 is sponsored by Peking University Sixth Hospital.

What drugs are being tested in NCT07590609?

Interventions in NCT07590609: XingpiJieyu Formula (XPJYF) + Escitalopram, XingpiJieyu Placebo + Escitalopram.

What condition does NCT07590609 study?

NCT07590609 studies Liver-Stagnation and Spleen-Deficiency, Severe Major Depression Disorder.

Is NCT07590609 still recruiting?

NCT07590609 is currently completed.

Last reviewed 2026-06-10 · How we verify

NCT07590609

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of XingpiJieyu Formula on Mitochondrial Energy Metabolism in Severe Liver-Stagnation and Spleen-Deficiency Depression.

Completed Phase 4

What this trial tests

Phase 4 trial testing XingpiJieyu Formula (XPJYF) + Escitalopram in Liver-Stagnation and Spleen-Deficiency in 150 participants. Completed in 31 January 2026.

Timeline

23 May 2023

31 January 2026

Quick facts

Lead sponsor	Peking University Sixth Hospital
Phase	Phase 4
Status	Completed
Enrollment	150
Start date	23 May 2023
Estimated completion	31 January 2026

Drugs / interventions tested

XingpiJieyu Formula (XPJYF) + Escitalopram
XingpiJieyu Placebo + Escitalopram

Conditions studied

Liver-Stagnation and Spleen-Deficiency — all drugs for Liver-Stagnation and Spleen-Deficiency →
Severe Major Depression Disorder — all drugs for Severe Major Depression Disorder →

Sponsor

Peking University Sixth Hospital

Who can join

Eligibility, any sex, with Liver-Stagnation and Spleen-Deficiency or Severe Major Depression Disorder.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Peking University Sixth Hospital trials

Trials by the same sponsor.

NCT07508215 — Efficacy of Spectrally Optimized Light on Cognitive Impairment in Major Depressive Disorder and Its Neuroimaging Mechani · NA · not yet recruiting
NCT07337473 — Evidence-based Digital CBT for Nonsuicidal Self-Injury · NA · not yet recruiting
NCT07173920 — Single-Center, Double-Blind, Randomized, Placebo-Controlled Study on Efficacy and Safety of rTMS (With Precise Localizat · NA · recruiting
NCT06913309 — Clinical Efficacy, Safety, and Applicability of Home-based Bright Light Therapy in Outpatient Adolescents With Major Dep · NA · recruiting
NCT06777459 — Study of Nitrate-Rich Juice on Cognitive Function in Heavy Alcohol Drinkers: a Two-Stage Adaptive Design Real-World Clin · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07590609 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University Sixth Hospital
Last refreshed: recently

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07590609.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing